Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV - 2Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 3Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 4Understanding Preschool Projects: Cultivating Abilities and Advancement
- 57 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- Extraordinary Shows to Long distance race on a Plane
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Most loved Public Dish: Which One Addresses Its Nation Best?
- UN panel says Israel operating 'de facto policy of torture'
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- Manual for 6 well known Amusement Park
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Vote in favor of your Number one Kind of Shades
- Electric Vehicles for Eco-Accommodating Driving
